Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 86.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 925,918 shares of the company's stock after buying an additional 430,014 shares during the period. Bank of America Corp DE owned approximately 1.65% of Protara Therapeutics worth $4,824,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Protara Therapeutics by 114.7% in the 2nd quarter. Geode Capital Management LLC now owns 744,519 shares of the company's stock valued at $2,256,000 after buying an additional 397,822 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Protara Therapeutics during the second quarter worth about $46,000. American Century Companies Inc. lifted its holdings in Protara Therapeutics by 69.8% during the second quarter. American Century Companies Inc. now owns 61,554 shares of the company's stock worth $187,000 after acquiring an additional 25,305 shares in the last quarter. New York State Common Retirement Fund bought a new position in Protara Therapeutics during the second quarter worth about $102,000. Finally, Invesco Ltd. acquired a new position in Protara Therapeutics in the second quarter valued at about $73,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.
Protara Therapeutics Stock Down 4.3%
TARA opened at $3.82 on Friday. Protara Therapeutics, Inc. has a 12-month low of $3.02 and a 12-month high of $7.82. The stock has a market cap of $225.76 million, a price-to-earnings ratio of -2.83 and a beta of 1.50. The business has a 50 day moving average of $4.02 and a 200-day moving average of $4.81.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.03). As a group, analysts expect that Protara Therapeutics, Inc. will post -1.48 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts recently commented on TARA shares. Oppenheimer boosted their price objective on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research report on Wednesday, May 20th. HC Wainwright reiterated a "buy" rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. UBS Group reissued a "buy" rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Cantor Fitzgerald restated an "overweight" rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Finally, Wall Street Zen cut Protara Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Protara Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.25.
Read Our Latest Stock Analysis on TARA
About Protara Therapeutics
(
Free Report)
Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.
Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
